MedTrace Logo

Assessing Ocular Surface Changes After Changing Glaucoma Medications

NCT00554411 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 22

Last updated 2017-01-27

No results posted yet for this study

Summary

Hypothesis: Changing to Travatan Z therapy increases the tear film break up time of subjects on Xalatan therapy presenting with ocular surface disease.

Conditions

  • Glaucoma
  • Monotherapy With Xalatan From 1 to 18 Months
  • Ocular Surface Disease

Sponsors & Collaborators

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Malik Y Kahook, M.D. · Rocky mountain Lions Eye Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00554411 on ClinicalTrials.gov